Lexington, Mass., November 23, 2021 - FUJIFILM Healthcare Americas Corporation, a leading provider of diagnostic and enterprise imaging solutions, announced two of its customers are using the company’s REiLI Artificial Intelligence (AI) platform in clinical practice. Capital Health of Pennington, NJ is using this platform for a solution that automatically and rapidly identifies and prioritizes suspected Intracranial Hemorrhage (ICH) for potential stroke patients, and the University Radiology Group (URG) located throughout New Jersey is using the platform to support their accelerated detection and diagnosis of breast cancer.
“Fujifilm strategically developed REiLI as an open, vendor-neutral platform that manages workflow and delivers AI results through our Synapse 7x diagnostic applications,” said Bill Lacy, senior vice president, medical informatics, FUJIFILM Healthcare Americas Corporation. “This is the answer for Synapse customers as to how they can connect Fujifilm-developed, or in the case of Capital Health and URG, third-party algorithm results directly into their Synapse PACS diagnostic workflow in the most impactful ways to accelerate clinical decisions.”
AI for Intracranial Hemorrhage Detection
ICH is the second most common subtype of stroke and typically leads to severe disability or death. Experts say only 12 to 39 percent of survivors can achieve long-term functional independence, and the overall incidence of spontaneous ICH in the U.S. is significant—with approximately 40,000 to 67,000 cases each year. With traumatic brain injury and stroke, early detection and treatment of hemorrhage leads to improved outcomes and can mean the difference between life and death.
With expertise in advanced imaging and treatment of vascular disease, Dr. Choudhri, director of vascular and interventional radiology and assistant director of radiology at Capital Health, and his team of neuroradiologists, are using REiLI to enable the MaxQ AI Accipio Suite. The combination of REiLI and Accipio Suite provides comprehensive, seamless and secure assessment of non-contrast head CT for ICH prioritization, triage, annotation, quantification and rule-out, which can result in the automatic and rapid identification and prioritization of potential stroke patients.